… ProQR to Release Topline Data from Proof of Concept Study of … program,” said Daniel de Boer, Chief Executive Officer of ProQR. “In our pre-clinical models QR-010 showed an … in this study include sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… ProQR Announces the Grant of two Key Patents, protecting … QR-010 for Cystic Fibrosis in the US and EU Key Updates ProQR received notice of grant for 2 key patents protecting … General Counsel and Chief Corporate Development Officer of ProQR. “We pursue a very aggressive patent strategy as our 16 …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
… ProQR annonce la publication dans Nature Medicine des données … CAMBRIDGE, Massachusetts, 18 déc. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société qui … commencer au cours du premier semestre 2019. À propos de ProQRProQR Therapeutics s’efforce de changer les vies grâce …
… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the …
… ProQR Strengthens its Scientific Advisory Board with the … SAB. Science is at the core of everything we do at ProQR, and with this group as our key advisors we can be more … of success that will be invaluable as we advance our R&D programs and our broader RNA technologies, including the …
… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … securities laws of any such state or jurisdiction. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Announces Closing of Underwritten Public Offering of … share. All of the shares are being offered by ProQR. The closing included the full exercise of the … securities laws of any such state or jurisdiction. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Announces Clearance of IND Application to Start … affected by this devastating disease,“ said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “Importantly, this trial is the first in ProQR’s …